Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 19/20 | 0.81 |
| ▸ | UGT1A4 | P22310 | 1/20 | 0.81 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.81 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | STS | P08842 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anastrozole SCHEMBL9726 | 0.90 | CYP19A1 (1.00) | CYP19A1UGT1A4PDE4DESR1STS | |
| Anastrozole SCHEMBL177942 | 0.90 | CYP19A1 (1.00) | CYP19A1UGT1A4PDE4DESR1STS | |
| Anastrozole SCHEMBL27927481 | 0.90 | CYP19A1 (1.00) | CYP19A1UGT1A4PDE4DESR1STS | |
| Anastrozole SCHEMBL28771766 | 0.89 | CYP19A1 (0.97) | CYP19A1UGT1A4PDE4DESR1STS | |
| Anastrozole SCHEMBL5917785 | 0.89 | CYP19A1 (0.97) | CYP19A1UGT1A4PDE4DESR1STS | |
| Anastrozole SCHEMBL3172308 | 0.89 | CYP19A1 (0.97) | CYP19A1UGT1A4PDE4DESR1STS | |
| SCHEMBL10324455 | 0.86 | CYP19A1 (0.92) | CYP19A1UGT1A4PDE4DESR1STS | |
| Anastrozole SCHEMBL13323739 | 0.85 | CYP19A1 (0.90) | CYP19A1UGT1A4PDE4DESR1STS | |
| SCHEMBL8059026 | 0.84 | CYP19A1 (0.87) | CYP19A1UGT1A4PDE4DESR1STS | |
| Anastrozole SCHEMBL354747 | 0.83 | CYP19A1 (0.85) | CYP19A1UGT1A4PDE4DESR1STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9549988-B2 | Pharmaceutical compounds targeted by MIF affinity-tethered moieties | RJS Biologics (US) | 2017-01-24 | — | — | US | disclosed |
| US-9505732-B2 | Auto magnetic metal salen complex compound | IHI CORPORATION (JP) | 2016-11-29 | — | — | US | disclosed |
| US-20160263074-A1 | METAL-SALEN COMPLEX COMPOUND, LOCAL ANESTHETIC AND ANTINEOPLASTIC DRUG | ISHIKAWA YOSHIHIRO (JP) | 2016-09-15 | — | — | US | disclosed |
| US-20150352217-A1 | Pharmaceutical Compounds Targeted by MIF Affinity-Tethered Moieties | RJS BIOLOGICS LLC | 2015-12-10 | — | — | US | disclosed |
| US-20150168424-A1 | IGFBP2 Biomarker | WANG YAN (US) | 2015-06-18 | — | — | US | disclosed |
| US-20140206635-A1 | METAL-SALEN COMPLEX COMPOUND, LOCAL ANESTHETIC AND ANTINEOPLASTIC DRUG | IHI CORPORATION (JP) | 2014-07-24 | — | — | US | disclosed |
| US-20140046021-A1 | SELF-MAGNETIC METAL-SALEN COMPLEX COMPOUND | IHI CORPORATION (JP) | 2014-02-13 | — | — | US | disclosed |
| US-8470860-B2 | Phenyl-sulfamates as aromatase inhibitors | STERIX LIMITED (GB) | 2013-06-25 | — | — | US | disclosed |
| US-8216571-B2 | Fully human anti-VEGF antibodies and methods of using | SCHERING CORPORATION (US) | 2012-07-10 | — | — | US | disclosed |
| US-20120029167-A1 | AUTO MAGNETIC METAL SALEN COMPLEX COMPOUND | YOSHIHIRO ISHIKAWA (JP) | 2012-02-02 | — | — | US | disclosed |
| US-7655806-B2 | Process for purification of anastrozole | SYNTHON BV (NL) | 2010-02-02 | — | — | US | disclosed |
| US-20090286989-A1 | Process for High Purity Anastrozole | SHILPA MEDICARE LTD. (IN) | 2009-11-19 | — | — | US | disclosed |
| US-20090247765-A1 | PROCESS FOR PREPARING PURE ANASTROZOLE | CADILA HEALTHCARE LIMITED (IN) | 2009-10-01 | — | — | US | disclosed |
| US-20090221837-A1 | Process for the Preparation of Pure Anastrozole | CADILA HEALTHCARE LIMITED (IN) | 2009-09-03 | — | — | US | disclosed |
| US-20080207915-A1 | Process for the Preparation of 2,2'-[5-(1H-1,2,4-Triazole-1-Ylmethyl) -1,3-Phenylene] Di (2-Methylpropionitrile) | USV LIMITED (IN) | 2008-08-28 | — | — | US | disclosed |
| US-20080112888-A1 | IGFBP2 BIOMARKER | SCHERING CORPORATION | 2008-05-15 | — | — | US | disclosed |
| US-20080096946-A1 | Process For The Preparation Of Anastrozole | GENERICS [UK] LIMITED (GB) | 2008-04-24 | — | — | US | disclosed |
| US-20080076933-A1 | PROCESS FOR MAKING ANASTROZOLE | SYNTHON BV (NL) | 2008-03-27 | — | — | US | disclosed |
| US-20070281982-A1 | PROCESS FOR PURIFICATION OF ANASTROZOLE | SYNTHON BV (NL) | 2007-12-06 | — | — | US | disclosed |
| US-20070117855-A1 | Phenyl-sulfamates as aromatase inhibitors | STERIX LIMITED (GB) | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150168424-A1 | IGFBP2 Biomarker | IGFBP2, IGFBP1, IGFBP5 | CYP19A1 379/4885UGT1A4 1685/4885PDE4D 4386/4885 |
| US-20080207915-A1 | Process for the Preparation of 2,2'-[5-(1H-1,2,4-Triazole-1-Ylmethyl) -1,3-Phenylene] Di (2-Methylpropionitrile) | CYP19A1, CYP11A1, HCN2 | CYP19A1 1/4885UGT1A4 2895/4885PDE4D 3218/4885 |
| US-20070117855-A1 | Phenyl-sulfamates as aromatase inhibitors | CYP19A1, CYP17A1, CYP21A2 | CYP19A1 1/4885UGT1A4 270/4885PDE4D 3642/4885 |
| US-20090221837-A1 | Process for the Preparation of Pure Anastrozole | CYP19A1, CYP4B1, CYP1B1 | CYP19A1 1/4885UGT1A4 295/4885PDE4D 1050/4885 |
| US-20120029167-A1 | AUTO MAGNETIC METAL SALEN COMPLEX COMPOUND | SDHB, SDHA, SLC40A1 | CYP19A1 1634/4885UGT1A4 2029/4885PDE4D 4684/4885 |
| US-20090286989-A1 | Process for High Purity Anastrozole | CYP19A1, CYP3A5, AURKC | CYP19A1 1/4885UGT1A4 1478/4885PDE4D 2131/4885 |
| US-20140206635-A1 | METAL-SALEN COMPLEX COMPOUND, LOCAL ANESTHETIC AND ANTINEOPLASTIC DRUG | NCLN, KCNN2, NCSTN | CYP19A1 3185/4885UGT1A4 3612/4885PDE4D 4688/4885 |
| US-20080112888-A1 | IGFBP2 BIOMARKER | IGFBP2, IGFBP1, IGFBP5 | CYP19A1 379/4885UGT1A4 1685/4885PDE4D 4386/4885 |
| US-20070281982-A1 | PROCESS FOR PURIFICATION OF ANASTROZOLE | CYP19A1, HSD17B11, ADH1A | CYP19A1 1/4885UGT1A4 254/4885PDE4D 1560/4885 |
| US-20080096946-A1 | Process For The Preparation Of Anastrozole | CYP19A1, CYP2C19, CYP3A4 | CYP19A1 1/4885UGT1A4 58/4885PDE4D 837/4885 |
| US-20140046021-A1 | SELF-MAGNETIC METAL-SALEN COMPLEX COMPOUND | SSBP1, KCNN1, IMMT | CYP19A1 3990/4885UGT1A4 3131/4885PDE4D 4378/4885 |
| US-20160263074-A1 | METAL-SALEN COMPLEX COMPOUND, LOCAL ANESTHETIC AND ANTINEOPLASTIC DRUG | NCLN, KCNN2, NCSTN | CYP19A1 3185/4885UGT1A4 3612/4885PDE4D 4688/4885 |
| US-20080076933-A1 | PROCESS FOR MAKING ANASTROZOLE | CYP19A1, CYP3A4, CYP2C19 | CYP19A1 1/4885UGT1A4 47/4885PDE4D 1598/4885 |
| US-20090247765-A1 | PROCESS FOR PREPARING PURE ANASTROZOLE | CYP19A1, PGR, GNRHR | CYP19A1 1/4885UGT1A4 275/4885PDE4D 165/4885 |
| US-20150352217-A1 | Pharmaceutical Compounds Targeted by MIF Affinity-Tethered Moieties | MIF, HMGB2, HMGB1 | CYP19A1 3268/4885UGT1A4 3392/4885PDE4D 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.